Home/Pipeline/P53

P53

Solid tumors

PreclinicalActive

Key Facts

Indication

Solid tumors

Phase

Preclinical

Status

Active

Company

Onco3R Therapeutics

About Onco3R Therapeutics

Onco3R Therapeutics is a Belgian clinical-stage biotech developing precision medicines for oncology and immunology with a portfolio of five disclosed programs. The company leverages a seasoned team with over 150 years of combined R&D experience and a dual-modality approach, utilizing both small molecules and antibodies to target clinically validated pathways. Its strategy focuses on designing best-in-class therapies by learning from the liabilities of first-generation drugs to improve safety and efficacy.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Solid tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed